Probability of achieving bone mineral density treatment goals with denosumab treatment in postmenopausal women with osteoporosis
Authors' conclusion
Our results demonstrate that the probability of achieving T-score targets with denosumab is dependent on baseline BMD, skeletal site, and treatment duration.
Study context
- Population
- Postmenopausal women >60 yr old with osteoporosis treated with denosumab for 3 or 10 yr in the FREEDOM trial and its long-term extension
- Primary endpoint
- Probability of achieving a non-osteoporotic T-score (>−2.5 or ≥−2.0) at the TH or LS
- Follow-up
- 3 or 10 yr
Primary result
As reported in the abstract
Probability of achieving T-score >−2.5 by baseline T-score · 3 yr of denosumab
- TH, baseline T-score −2.7
- 71%
- TH, baseline T-score −3.0
- 12%
- TH, baseline T-score −3.5
- 0.1%
- LS, baseline T-score −2.7
- 86%
- LS, baseline T-score −3.0
- 59%
- LS, baseline T-score −3.5
- 11%
- Baseline T-score permitting ≥50% to achieve T-score >−2.5 at 3 yr, TH
- −2.8
- Baseline T-score permitting ≥50% to achieve T-score >−2.5 at 3 yr, LS
- −3.1
Further findings
Probability of achieving T-score >−2.5 with longer treatment · up to 10 yr
- Baseline T-score permitting ≥50% to achieve T-score >−2.5 at 10 yr, TH
- −3.0
- Baseline T-score permitting ≥50% to achieve T-score >−2.5 at 10 yr, LS
- −3.7
- Longer treatment duration of up to 10 yr increased the probability of achieving target T-scores
Probability of achieving higher target (T-score ≥ −2.0)
- Overall probabilities lower at both sites, particularly TH, even with longer treatment
Original publication
Probability of achieving bone mineral density treatment goals with denosumab treatment in postmenopausal women with osteoporosis. J Bone Miner Res. Published 25 January 2025. doi:10.
Composed by AI from the published abstract and checked against it. How Briefs are made →